Among them, evidence obtained in preclinical tumor models has indicated that IL-27 has a potent antitumor activity, not only through induction of tumor-specific Th1 and cytotoxic T lymphocyte (CTL) responses, but also having direct inhibitory effects on tumor cell proliferation, survival, invasiveness, and angiogenic potential [45]. This evidence concerns the gene IL27 and neoplasm.